Last updated: November 1, 2026
The PEGASYS COPEGUS Combination Pack was a co-packaged hepatitis C treatment containing peginterferon alfa-2a and ribavirin. Its commercial position deteriorated rapidly after the launch of direct-acting antivirals such as Sovaldi, Harvoni, and Viekira Pak. The combination pack is no longer a competitive standard of care in the United States, and Roche has not reported separate revenue for the pack.
Its economic history has four phases:
- Regulatory adoption in the early 2000s.
- Expansion as a peginterferon-based hepatitis C regimen.
- Rapid market contraction from 2014 as all-oral direct-acting antivirals became available.
- Commercial obsolescence after broad uptake of shorter, better-tolerated curative regimens.
What was the PEGASYS COPEGUS Combination Pack?
The PEGASYS COPEGUS Combination Pack was a co-pack, not a single fixed-dose tablet.
| Component |
Active ingredient |
Drug class |
Typical role |
| PEGASYS |
Peginterferon alfa-2a |
Long-acting interferon |
Weekly injectable antiviral and immune modulator |
| COPEGUS |
Ribavirin |
Nucleoside analogue antiviral |
Oral combination partner |
PEGASYS was administered by subcutaneous injection. COPEGUS was administered orally, generally on a weight-based schedule. Treatment duration varied by hepatitis C genotype, prior treatment history, viral response, and patient characteristics.
The products were used primarily for chronic hepatitis C virus infection. PEGASYS also had a separate hepatitis B indication, but that indication did not create a durable market for the combination pack because COPEGUS was not part of standard hepatitis B treatment.
When did PEGASYS and COPEGUS lose exclusivity?
PEGASYS and COPEGUS lost commercial exclusivity in stages rather than on one common date.
| Product |
U.S. regulatory pathway |
Commercial exclusivity profile |
Market impact |
| PEGASYS |
Biologics license application |
Biologic exclusivity and patent protection operated separately |
Biosimilar and follow-on competition was less important than therapeutic substitution by direct-acting antivirals |
| COPEGUS |
New drug application |
Small-molecule patent and regulatory exclusivity framework |
Generic ribavirin competition reduced product differentiation |
| Combination Pack |
Co-packaged regimen |
No independent clinical exclusivity for the pack itself |
The pack declined when the underlying regimen became clinically obsolete |
The key commercial loss did not come from a single patent expiration. It came from therapeutic displacement. Before the direct-acting antiviral era, peginterferon plus ribavirin was a central hepatitis C treatment approach. After 2013, all-oral regimens delivered higher cure rates, shorter treatment periods, and fewer systemic adverse effects.
The FDA approved PEGASYS in 2002 for chronic hepatitis C, including use with ribavirin, and approved COPEGUS for use with PEGASYS in the same general treatment era.[1][2]
What was the FDA status of the PEGASYS COPEGUS Combination Pack?
The combination pack reflected an approved treatment strategy rather than a new active pharmaceutical ingredient.
PEGASYS had FDA approval as a biologic product. COPEGUS had FDA approval as a ribavirin product. The pack did not establish a separate biologic mechanism, new molecular entity, or independent therapeutic class.
FDA milestones
| Date |
Event |
Commercial significance |
| 2002 |
FDA approval of PEGASYS for chronic hepatitis C |
Established peginterferon alfa-2a as a major hepatitis C product |
| 2002 |
FDA approval of COPEGUS for combination use with PEGASYS |
Created a branded ribavirin partner for the PEGASYS regimen |
| 2011 |
First-generation direct-acting antivirals entered the market |
Began reducing reliance on interferon-based treatment |
| 2013-2014 |
Sofosbuvir-based and other all-oral regimens launched |
Accelerated substitution away from PEGASYS and COPEGUS |
| 2014 onward |
Guidelines increasingly favored interferon-free therapy |
Reduced new starts and shortened the commercial life of the pack |
The FDA’s approval of newer direct-acting antivirals changed the treatment algorithm. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America now recommend direct-acting antiviral regimens rather than peginterferon-ribavirin for most patients with chronic hepatitis C.[3]
What was the financial trajectory of PEGASYS?
Roche reported PEGASYS sales at the brand level, but it did not separately disclose revenue for the PEGASYS COPEGUS Combination Pack. Roche also did not report a separate global revenue line for COPEGUS in its annual financial statements.
Publicly available financial data show a sharp decline in PEGASYS sales after direct-acting antiviral launches.
| Period |
Financial direction |
Primary driver |
| Early to mid-2000s |
Growth and high commercial value |
Limited effective treatment alternatives |
| 2011-2013 |
Pressure begins |
First-generation direct-acting antivirals reduce interferon use |
| 2014-2016 |
Rapid decline |
Sovaldi, Harvoni, and competing oral therapies displace the regimen |
| 2017 onward |
Residual or immaterial HCV contribution |
Narrow legacy use and loss of clinical preference |
Roche’s reported PEGASYS revenue declined substantially during the second half of the 2010s. The company attributed the contraction to competition from newer hepatitis C medicines and lower demand for interferon-based treatment.[4][5]
The pack’s revenue would have declined faster than the broader PEGASYS franchise because its value depended on the continued use of ribavirin. As physicians shifted to interferon-free treatment, both components became less commercially relevant for hepatitis C.
How did direct-acting antivirals change the market?
Direct-acting antivirals changed the market through efficacy, tolerability, duration, and convenience.
| Attribute |
PEGASYS plus COPEGUS |
Modern direct-acting antiviral regimens |
| Administration |
Weekly injection plus oral tablets |
Oral tablets |
| Typical treatment burden |
Often 24 to 48 weeks |
Often 8 to 12 weeks |
| Adverse-effect profile |
Flu-like symptoms, cytopenias, psychiatric and systemic effects |
Generally lower treatment burden |
| Cure rates |
Materially lower than modern regimens |
Commonly above 90% in appropriate populations |
| Genotype coverage |
More dependent on genotype and response |
Broader pangenotypic options |
| Monitoring burden |
High |
Lower in many patient populations |
| Market role |
Historical standard |
Legacy therapy, no longer first-line |
The economic consequence was a substitution event rather than a gradual generic erosion event. Generic ribavirin could reduce the price of COPEGUS, but it could not preserve demand for a treatment regimen that clinicians increasingly viewed as inferior.
What patent and exclusivity protections covered the products?
The relevant IP estate consisted of separate rights around peginterferon, ribavirin, formulations, manufacturing, and treatment methods. The co-pack itself was unlikely to create a commercially durable patent moat independent of the underlying products.
PEGASYS patent position
PEGASYS was protected through patents covering pegylated interferon compositions and related manufacturing or conjugation technology. Some of those rights predated the product’s 2002 approval and had finite terms that largely expired or became commercially irrelevant during the 2010s.
Because PEGASYS is a biologic, the U.S. framework differs from a conventional small-molecule product. The Orange Book is principally used for approved drug products and patent certifications involving NDAs. Biologic patent information and biosimilar-related exclusivity are handled through separate FDA and patent mechanisms.
COPEGUS patent position
COPEGUS was a ribavirin product. Its commercial protection depended on conventional drug patents, regulatory exclusivity, branding, and manufacturing economics. Ribavirin itself was an established antiviral compound, making long-term product differentiation difficult once generic products became available.
Formulation and method-of-use rights
Potential protection categories included:
- Pegylated interferon composition claims.
- Conjugation and purification processes.
- Injectable formulations and stability claims.
- Ribavirin tablet formulations.
- Treatment methods involving genotype, viral response, or dosing.
- Combination-use claims involving interferon and ribavirin.
These rights did not provide a lasting barrier against direct-acting antiviral substitution. A patent can protect a formulation or method without preserving demand for the product if the treatment standard changes.
What was the Paragraph IV and generic-entry risk?
COPEGUS carried conventional small-molecule generic-entry risk. Generic ribavirin manufacturers could challenge listed patents through the Abbreviated New Drug Application pathway, including Paragraph IV certifications where applicable.
PEGASYS faced a different competitive structure. A follow-on biologic or biosimilar would require a biologics pathway and would not automatically recreate the historical PEGASYS-COPEGUS market. By the time biosimilar competition became commercially relevant, the more important risk was direct substitution by oral direct-acting antivirals.
The practical generic-entry scenarios were:
| Scenario |
Likely effect |
| Generic ribavirin entry |
Lower COPEGUS price and reduced branded demand |
| PEGASYS biosimilar or follow-on competition |
Potential price pressure, but limited impact on a declining indication |
| New interferon-ribavirin patent challenge |
Limited commercial value because clinical use had already contracted |
| Direct-acting antiviral competition |
Largest source of revenue loss |
What is the current commercial status?
The PEGASYS COPEGUS Combination Pack has no meaningful position in current U.S. hepatitis C treatment guidelines. The regimen is not competitive with approved oral direct-acting antiviral therapies.
Current commercial characteristics include:
- No separately disclosed pack revenue.
- No material growth driver in hepatitis C.
- Limited relevance to current treatment guidelines.
- Minimal strategic value relative to direct-acting antivirals.
- Higher manufacturing and administration burden than oral alternatives.
- Residual use, if any, tied to exceptional clinical circumstances rather than routine treatment.
PEGASYS may retain historical relevance or limited value in other indications and markets, but that should not be confused with demand for the PEGASYS-COPEGUS hepatitis C combination.
How strong is the patent estate for PEGASYS COPEGUS?
The patent estate is commercially weak for the combination as a current product.
| Strength factor |
Assessment |
| Composition-of-matter protection |
Limited practical value at this stage |
| Formulation protection |
Narrow and vulnerable to design-around or expiration |
| Method-of-use protection |
Reduced value because guidelines favor other regimens |
| Manufacturing know-how |
May create operational barriers, but not demand |
| Biosimilar barriers |
Less important than therapeutic substitution |
| Geographic coverage |
Varies by country and remaining patent term |
| Litigation leverage |
Low relative to the product’s former market position |
The core weakness is market dependence on an obsolete treatment strategy. Patent rights cannot compensate for inferior clinical performance when payers and prescribers have effective substitutes.
What licensing deals and partnerships affected the product?
Roche developed and commercialized PEGASYS and COPEGUS within its broader hepatitis franchise. Public financial disclosures do not identify a material third-party licensing transaction specifically for the PEGASYS COPEGUS Combination Pack that would materially change its revenue trajectory.
The principal commercial value came from Roche’s control of:
- PEGASYS development and manufacturing.
- Branded commercialization.
- Regulatory approvals.
- Combination positioning with COPEGUS.
- Global hepatitis treatment infrastructure.
The franchise’s decline was driven by market competition and clinical displacement, not by the loss of a major licensing partner.
What generic launch scenarios remain?
A generic launch would have limited effect on the broader hepatitis C market because most patients have already moved to oral direct-acting antiviral therapy.
Scenario analysis
| Scenario |
Market outcome |
| Generic COPEGUS remains available |
Ribavirin access continues at lower prices for residual uses |
| Branded PEGASYS remains available in selected markets |
Sales remain niche and geography-dependent |
| Follow-on peginterferon enters |
Price erosion with limited volume recovery |
| Payer mandates modern oral therapy |
Further contraction of interferon-ribavirin demand |
| Supply disruption affects alternatives |
Temporary niche demand could occur, but not a durable recovery |
The highest probability outcome is continued erosion, with residual demand concentrated in jurisdictions or clinical settings where access to modern direct-acting antivirals remains constrained.
What revenue exposure remains for Roche?
Revenue exposure is now immaterial compared with Roche’s major oncology, immunology, neuroscience, and diagnostics businesses. The historical PEGASYS franchise generated substantial revenue during the interferon era, but the combination pack did not remain a meaningful growth asset after the direct-acting antiviral transition.
Roche’s financial risk from the product is therefore limited to:
- Residual sales erosion.
- Inventory and manufacturing costs.
- Regulatory maintenance costs.
- Supply obligations in selected markets.
- Potential product discontinuation or market withdrawal costs.
There is no credible basis to treat the combination pack as a current revenue-growth opportunity without a major change in hepatitis C treatment access or clinical practice.
Key Takeaways
- PEGASYS COPEGUS was a co-packaged peginterferon-ribavirin regimen for hepatitis C.
- The products were commercially important before the direct-acting antiviral era.
- Sovaldi, Harvoni, Viekira Pak, and later pangenotypic therapies caused rapid therapeutic substitution.
- Roche did not separately report revenue for the combination pack.
- COPEGUS faced conventional generic competition, while PEGASYS operated under the biologic framework.
- The principal commercial loss came from clinical obsolescence, not a single patent expiration.
- The combination has no material role in current U.S. hepatitis C treatment guidelines.
- Residual value is limited to legacy markets, exceptional clinical use, and selected non-U.S. settings.
- The current patent estate has little ability to restore demand or support a meaningful revenue recovery.
FAQs
Is PEGASYS COPEGUS still approved for hepatitis C?
The component products received FDA approvals for hepatitis C treatment, but the regimen is no longer a preferred modern treatment strategy. Current clinical guidance favors oral direct-acting antivirals.[3]
Did the PEGASYS COPEGUS pack have its own patent?
The commercial protection primarily came from patents and regulatory rights covering PEGASYS, COPEGUS, their formulations, manufacturing, and use. A co-pack does not automatically create a separate, durable patent estate.
Can a generic company launch COPEGUS?
Generic ribavirin products can compete with branded COPEGUS subject to applicable FDA approvals, patents, and market availability. Generic ribavirin does not recreate the former PEGASYS-based hepatitis C market.
Was PEGASYS revenue reported separately from COPEGUS revenue?
Roche reported PEGASYS at the brand or franchise level in annual financial disclosures. It did not provide a separately reported revenue line for the PEGASYS COPEGUS Combination Pack.
Does PEGASYS still have value outside hepatitis C?
PEGASYS had a separate hepatitis B indication and may retain historical or limited market relevance in selected jurisdictions. That value is distinct from the PEGASYS-COPEGUS combination, which depended on the former interferon-based hepatitis C treatment model.
References
-
U.S. Food and Drug Administration. (2002). PEGASYS (peginterferon alfa-2a) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2002). COPEGUS (ribavirin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
American Association for the Study of Liver Diseases & Infectious Diseases Society of America. (2024). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/
-
Roche Holding Ltd. (2014). Roche annual report 2014. https://www.roche.com/investors/reports
-
Roche Holding Ltd. (2016). Roche annual report 2016. https://www.roche.com/investors/reports
